Bioactivity | Mometasone furoate (Sch32088) is a glucocorticoid receptor agonist with anti-inflammatory and anti-allergic activity. Mometasone furoate acts as a corticosteroid agent and used for topical applications in chronic skin eczema and airway inflammation management of asthma in vivo[1] | ||||||||||||
Target | IC50: Glucocorticoid Receptor | ||||||||||||
Invitro | Mometasone furoate binds to a glucocorticoid receptor causes conformational changes in the receptor, separation from chaperones, and the receptor moves to the nucleus[1].Mometasone furoate (0.1-10 μM; 2h before LPS stimulation) strongly inhibits LPS-stimulated nitrite production in a concentration-dependent manner in J774 macrophages, The IC50 value is 0.00024 μM for Mometasone furoate in J774 cells[1].Mometasone furoate (0.1-10 μM; 2h before LPS stimulation) is more potent than DEX, it significantly inhibits iNOS expression at a 0.01 µM concentration whereas Dex became active at 0.1 µM. Additionally, the inhibition of cox-2 protein expression at 0.01 μM is 79% for Mometasone furoate and 39% for Dex[1]. | ||||||||||||
Name | Mometasone furoate | ||||||||||||
CAS | 83919-23-7 | ||||||||||||
Formula | C27H30Cl2O6 | ||||||||||||
Molar Mass | 521.43 | ||||||||||||
Appearance | Solid | ||||||||||||
Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
Storage |
|
||||||||||||
Reference | [1]. Maria Galuppo, et al. Use of Mometasone furoate in prolonged treatment of experimental spinal cord injury in mice: A comparative study of three different glucocorticoids. Pharmacol Res. 2015 Sep;99:316-28 [2]. https://go.drugbank.com/drugs/DB14512 |